Investigational drug · Phase 2
BI 770371
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH).
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "BI 770371"
First trial start
2025
Jan 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 770371", any sponsor or status.
Conditions studied
As listed on its trial records.
- Compensated Liver Cirrhosis
- Metabolic Dysfunction Associated Steatohepatitis (MASH)
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 770371" as an intervention, largest first.
- A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06806852 · 91 participants · Start May 14, 2025 · Primary completion Aug 31, 2027
Drug: BI 770371; Pembrolizumab and 1 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Louisville, Kentucky; Minneapolis, Minnesota; Columbus, Ohio · 51 sites in all
- A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are ToleratedActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT05327946 · 42 participants · Start May 17, 2022 · Primary completion Jul 16, 2024
Drug: BI 770371; ezabenlimab · For: Solid Tumors
Sites: Sarasota, Florida; Hackensack, New Jersey; Montreal, Canada · 5 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT06675929 · 28 participants · Start Jan 20, 2025 · Primary completion Jan 13, 2026
Drug: BI 770371; Placebo for BI 770371 · For: Compensated Liver Cirrhosis; Metabolic Dysfunction Associated Steatohepatitis (MASH)
Sites: Chandler, Arizona; Coronado, California; Montclair, California · 13 sites in all
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT05068102 · 14 participants · Start Mar 3, 2022 · Primary completion Jan 22, 2026
Drug: BI 765063; Ezabenlimab and 3 more · For: Carcinoma, Squamous Cell of Head and Neck (HNSCC); Melanoma; Non-small Cell Lung Cancer (NSCLC)
Sites: Amsterdam, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.